Spanish biotechnology concentrates on cancer

According to the Spanish Association of Bioenterprises (ASEBIO), seventy-two innovative drugs are being researched for ninety different indications by nineteen Spanish biotech companies

10-Apr-2008

The Spanish Association of Bioenterprises (ASEBIO) has presented a poster with the portfolio of healthcare products that are being researched by Spanish biotech companies. This Spanish sector pipeline includes 28 companies contributing a total of 119 projects on drugs and diagnosis systems for use on humans and 12 products for animal health care.

Jorge Barrero, ASEBIO General Secretary has highlighted that "this presentation initiative from the Spanish biotechnology sector forms part of a more ambitious programme of activities that will culminate in Granada during the month of September with the BIOSPAIN 2008 International Convention." The goal pursued by this event, which comprises a science congress, an investor forum and bilateral meetings to forge alliances, is "to give international projection to the capacities of Spanish biotechnology and attract the attention of the world pharmaceutical market regarding the opportunities that exist for collaboration with our country's biotech companies."

Among the 19 companies that are developing drugs, the most outstanding is Pharmamar, which in 2007 marketed the first innovative cancer drug developed in Spain. There are other products in the advanced clinical phase (phase III), including the Cellerix cell therapy for treatment of complex fistulas and Palau Pharma's coronary stent in the cardiovascular field. Other Spanish biotech companies, such as Neuropharma, Advancell, Digna Biotech, Archivel, Thrombotargets or Fina biotech, have more recently entered into clinical phases. In total, ASEBIO has reports of 40 developments in clinical phases (3 in phase III, 24 in phase II and 13 in Phase I) and 50 projects in the preclinical phase.

Furthermore, the ASEBIO survey reports 26 new disease diagnosis and prognosis systems, some are which are soon to come out onto the market. Likewise, in the medical supplies field, the PRGF regeneration technology developed by BTI, a company from the Basque province of Álava, also stands out.

https://www.bionity.com/en/news/80620/spanish-biotechnology-concentrates-on-cancer.html